The project “Novel individualized therapies in JAK/STAT driven T-cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK STAT pathway in mature T-cell lymphomas and to detect potent drugs and drug synergisms targeting this pathway.
The consortium of six research groups from Cologne (Marco Herling), Helsinki (Satu Mustjoki, Tero Aittokallio), Toronto (Patrick Gunning, Benjamin Haibe-Kains), Vienna (Heidi Neubauer), will mainly focus on the entities of T-cell prolymphocytic leukemia (T-PLL) and T-cell large granular lymphocyte leukemia (T-LGL), both showing a high incidence of missense mutations in JAK STAT pathway genes.
The consortium led by Satu Mustjoki will receive €1,562,000 in ERA PerMed funding, of which €300,000 is allocated to the group in Cologne.
The consortium will ultimately integrate drug screen data into clinical trials and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data.
For more details visit: